AstraZeneca used its third-quarter pipeline update to cut two early prostate cancer programs, trimming back assets that had only recently entered human testing. The moves affected AZD9750, an orally bioavailable androgen receptor degrader, and AZD8359, a STEAP2-targeting T-cell engager.
The decisions matter less for near-term revenue than for what they say about portfolio discipline. Both programs were built to address known limitations in existing prostate cancer approaches, but AstraZeneca exited quickly rather than continue broad enrollment once the early signal no longer supported the investment case.
The programs
AstraZeneca axed AZD9750 in response to pharmacokinetic and pharmacodynamic data. The company had taken the drug into the clinic in January and had initially expected to treat 300 patients across a phase 1/2 study. Early this month, however, AstraZeneca stopped recruiting after enrolling six participants.
AZD9750 was designed to address resistance that can emerge with androgen receptor pathway inhibitors such as Pfizer's Xtandi. In preclinical testing, the candidate degraded mutant and amplified forms of the receptor, and AstraZeneca had optimized the molecule's oral bioavailability in rodents. That preclinical rationale did not survive the early PK/PD read from patients.
AZD8359 was also removed from the pipeline, with AstraZeneca citing strategic reasons. The company had started a first-in-human trial in May, and the phase 1/2 study was supposed to enroll 42 people with metastatic prostate cancer and finish late next year.
That asset targeted STEAP2, a prostate-associated surface antigen, through a T-cell engager biased toward CD8-positive rather than CD4-positive T cells. AstraZeneca's design aimed to reduce cytokine release syndrome and off-tumor activity, two constraints that can limit T-cell engager dosing. In vitro, the company said AZD8359 killed tumor cells while reducing cytokine release by 40% compared with a conventional T-cell engager.
Broader pipeline signal
The two prostate cancer cuts were half of four early-phase programs AstraZeneca culled this quarter. The company also ended work on AZD2962, an IRAK4 inhibitor for hematological malignancies, and AZD8421, a CDK2 inhibitor for solid tumors.
AZD8421 had been intended to enroll 564 patients in a phase 1/2a study that began in 2023, but AstraZeneca closed the trial to new participants this month after recruiting 55 subjects. The candidate came from the company's attempt to improve on first-generation CDK2 inhibitors by increasing selectivity for CDK2 over CDK1 to reduce toxicity.
Taken together, the update suggests AstraZeneca is willing to cut early oncology assets quickly when emerging clinical data or portfolio prioritization no longer justify a larger spend. In a crowded prostate cancer field, speed of termination can be as important strategically as speed of advancement.
